Pre Clinical Assessment
What is pre clinical assessment?
For pharmaceutical products pre-clinical development — or non-clinical assessment — refers to the process through which investigational drugs are subjected to extensive laboratory testing (in vitro and in vivo testing) to determine their safety profiles; such assessment in intended to ensure risk to human subjects is minimised or eliminated completely.
This stage of pharmaceutical development can take between one to five years and provides information about the pharmaceutical composition of the drug, its safety, how it will be formulated and manufactured, and how it will be administered to human subjects during clinical trials.
Pre clinical assessment overview
Medical Devices that do not have a drug moiety are not required to undergo pre-clinical testing and instead undergo GLP testing for safety assessment of the device and its components. Some medical devices will also undergo biocompatibility testing to show whether a component of the device, or all components, are sustainable in a living model.
The results of preclinical and non-clinical testing are typically used to determine:
• Manufacturing and formulation strategies for the drug tailored for its intended clinical use
• Analytical development strategies
• Toxicology considerations
• Product quality specification and testing development
• Product registration strategies
The regulatory agencies are required by law to review specific tests, documentation, and results before granting approval to begin the next stage of product development which include clinical testing in humans.
Consideration is also given to technology transfer and validation master plans at the pre-clinical development stage, along with developing quality systems. Although not formally required until the later clinical development stages, development of quality systems and quality controls can help to refine and speed up their implementation when they become a formal requirement at clinical phase III and beyond.
Need further information?
WBR provides strategic advice to clients on the activities required for the pre-clinical or non-clinical development stage. Woodley BioReg helps to design and implement systems and processes to significantly enhance client product development timelines. This typically includes:
• Development and training in QA systems
• Preparation of documentation – SOPs, reports, licence sections, protocols, Master Validation Plans, etc.
• Planning and implementing technology transfer
• Process development
• Programme and project management